Teva Pharmaceutical Industries Limited

TEVANYSEHealthcare● Active

$34.19

$-0.24(-0.70%)

Market Cap$39.8B

P/E Ratio—

52W High$37.35

52W Low$14.99

Avg Volume6.7M

Open$34.30

Beta0.85

Free Cash Flow Financials Revenue

Teva Pharmaceutical Industries Limited (TEVA) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

TEVA · free cash flow · updated Jun 8, 2026

Core FCF metrics

TEVA · FCF · TTM · margin & CAGR

Free cash flow was $1.15B for FY2025 (fiscal year ending 2025-12-31), up 53.3% year-over-year The FCF margin was 6.7%. Five-year CAGR stands at +12.5%.

FY2025 Free Cash Flow$1.15B▲ +53.3% YoY

Trailing 12M (TTM)$1.17Btrailing 4 quarters sum

FCF Margin6.7%$1.15B ÷ revenue

3-Year CAGR+3.3%FY2022 → FY2025

5-Year CAGR+12.5%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

TEVA · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$1.65B(501M)$1.15B▲ +53.3%6.7%

FY2024$1.25B(498M)$749.0M▼ 11.0%4.5%

FY2023$1.37B(526M)$842.0M▼ 19.2%5.3%

FY2022$1.59B(548M)$1.04B▲ +341.5%7.0%

FY2021$798.0M(562M)$236.0M▼ 63.0%1.5%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

TEVA · P/FCF · FCF yield · FCF per share

Teva Pharmaceutical Industries Limited (TEVA) trades at a FCF yield of 4.74% and a price-to-free-cash-flow ratio of 33.5x. FCF per share stands at $1.02, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

4.74%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$1.02

TTM FCF ÷ Shares Outstanding

Price / FCF

x33.5

Share Price ÷ FCF per Share

EV / FCF (TTM)

x28.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

TEVA · cash flow statement · operating / investing / financing

For FY2025, Teva Pharmaceutical Industries Limited generated $1.65B in operating cash flow and spent 501M in capital expenditures, yielding $1.15B in free cash flow.

Operating Activities

+$1.65B

Cash from core business operations

2025-12-31

Investing Activities

+$737.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$2.15B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($1.65B) − |CapEx| (501M) = FCF ($1.15B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

TEVA vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Teva Pharmaceutical Industries LimitedYOU

TEVA

$1.15B+53.3%6.7%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Teva Pharmaceutical Industries Limited (TEVA) reported free cash flow of $1.15B for FY2025 (fiscal year ending 2025-12-31), up 53.3% year-over-year. The FCF margin was 6.7%.

Based on available data, Teva Pharmaceutical Industries Limited has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $4.77B in FY2015. The 5-year CAGR stands at +12.5%.

Teva Pharmaceutical Industries Limited's FCF yield is 4.74% and price-to-FCF ratio is 33.5x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

TEVA free cash flow · 8 questions

Teva Pharmaceutical Industries Limited free cash flow was $1.15B for FY2025, up 53.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $1.17B.

TEVA free cash flowTEVA FCFTEVA FCF 2025TEVA free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Teva Pharmaceutical Industries Limited · Teva Pharmaceutical Industries Limited SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026